Products for Research Use Only

Blinatumomab

CAT: 0804-HY-P9963-01Size: 100 µgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9963-01Size:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].
CAS Number
853426-35-4
Product Name Alternative
Anatumomab; bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO
UNSPSC
12352203
Target
CD19
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/blinatumomab.html
Purity
98.78
Solubility
H2O
Smiles
[Blinatumomab]
Molecular Weight
(54.09 kDa)
References & Citations
[1]Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376 (9) :836-847. |[2]Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003 Apr 15;170 (8) :4397-402.|[3]Hoffman LM, et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE (®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014 Mar 31;4:63. |[4]Zhang R, et al. The establishment and application of CD3E humanized mice in immunotherapy[J]. Experimental Animals, 2022, 71 (4) : 442-450.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched